Stocks to Watch: GameStop, Merck, Bowman Consulting
By Ben Glickman
GameStop's sales fell 19% in the fourth quarter to $1.79 billion, though the video-game retailer's profit rose. Shares fell 15%, to $13.15, after hours.
Merck's treatment for pulmonary arterial hypertension was approved by regulators in the U.S. on Tuesday. The pharmaceutical giant paid $11.5 billion to acquire the company developing the treatment, called Winrevair, in 2021. Shares rose 4.8%, to $131.50, after hours.
Bowman Consulting Group said it was launching a $50 million public offering of stock, about 10% of which will come directly from executives. The company plans to use the proceeds for general purposes, including potential acquisitions or possible debt repayment. Shares fell 9.3%, to $35.80, after hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 26, 2024 19:51 ET (23:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?